{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:19:34Z","timestamp":1782991174057,"version":"3.54.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Acute intermittent porphyria (AIP) causes neurovisceral symptoms and organ toxicity resulting in acute and chronic health conditions. Treatment has traditionally involved avoiding triggers and utilizing carbohydrates and hemin infusions for acute attacks. Givosiran, an FDA-approved small interfering RNA, has shown benefit in adults in reducing attacks. However, its usage in pediatrics is extremely limited. We present a pediatric patient with AIP, requiring frequent hemin infusions for severe attacks, which have a resolution of her disease state and symptoms with the initiation of givosiran therapy.<\/jats:p>","DOI":"10.1097\/mph.0000000000002941","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:26:18Z","timestamp":1724448378000},"page":"e524-e527","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-8993","authenticated-orcid":false,"given":"Kenneth E.","family":"Bujold","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Baystate Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kasher","sequence":"additional","affiliation":[{"name":"Division of Medicine-Pediatrics, Baystate Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McKiernan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Baystate Children\u2019s Hospital, University of Massachusetts Chan Medical School\u2014Baystate, Springfield, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1297","article-title":"Acute hepatic porphyrias: review and recent progress","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol Commun"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5152\/TurkArchPediatr.2022.22301","article-title":"An overview of acute hepatic porphyrias: clinical implications, diagnostic approaches, and management strategies","volume":"58","author":"Z\u00fcbario\u011flu","year":"2023","journal-title":"Turk Arch Pediatr"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","journal-title":"Am J Med"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2016.08.006","article-title":"Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study","volume":"119","author":"Naik","year":"2016","journal-title":"Mol Genet Metab"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10545-018-0178-z","article-title":"Medical and financial burden of acute intermittent porphyria","volume":"41","author":"Neeleman","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2022.11.034","article-title":"AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ymgme.2016.10.005","article-title":"Acute intermittent porphyria in children: a case report and review of the literature","volume":"119","author":"Balwani","year":"2016","journal-title":"Mol Genet Metab"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/088307388600100106","article-title":"Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature","volume":"1","author":"Kaplan","year":"1986","journal-title":"J Child Neurol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20250804","first-page":"3268","article-title":"Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report","volume":"28","author":"Mazzoli","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17474124.2022.2110469","article-title":"Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran","volume":"16","author":"Ventura","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.metabol.2010.05.016","article-title":"Preliminary report: hyperhomocysteinemia in patients with acute intermittent porphyria","volume":"59","author":"To-Figueras","year":"2010","journal-title":"Metabolism"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jimd.12391","article-title":"Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran","volume":"44","author":"To-Figueras","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2022.01.002","article-title":"Givosiran in acute intermittent porphyria: a personalized medicine approach","volume":"135","author":"Poli","year":"2022","journal-title":"Mol Genet Metab"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/ki.2015.97","article-title":"High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria","volume":"88","author":"Pallet","year":"2015","journal-title":"Kidney Int"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jimd.12583","article-title":"Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: a matched cohort study in 1244 individuals","volume":"46","author":"Lissing","year":"2023","journal-title":"J Inherit Metab Dis"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ekir.2021.04.004","article-title":"Renal function decline under therapy with small interfering RNA silencing ALAS1 for acute intermittent porphyria","volume":"6","author":"Lazareth","year":"2021","journal-title":"Kidney Int Rep"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:02:07Z","timestamp":1754337727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002941","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"2024-05-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}